Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Invested Capital (2018 - 2024)

Historic Return on Invested Capital for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Q3 2025 value amounting to 6.83%.

  • Ultragenyx Pharmaceutical's Return on Invested Capital fell 54600.0% to 6.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.83%, marking a year-over-year decrease of 54600.0%. This contributed to the annual value of 2.03% for FY2024, which is 2200.0% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Return on Invested Capital is 6.83%, which was down 54600.0% from 3.44% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Return on Invested Capital's 5-year high stood at 0.29% during Q1 2021, with a 5-year trough of 7.4% in Q3 2023.
  • In the last 5 years, Ultragenyx Pharmaceutical's Return on Invested Capital had a median value of 1.79% in 2024 and averaged 2.28%.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Return on Invested Capital tumbled by -63300bps in 2023 and then skyrocketed by 60300bps in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Return on Invested Capital stood at 0.41% in 2021, then tumbled by -287bps to 1.6% in 2022, then crashed by -131bps to 3.7% in 2023, then soared by 52bps to 1.79% in 2024, then crashed by -282bps to 6.83% in 2025.
  • Its Return on Invested Capital stands at 6.83% for Q3 2025, versus 3.44% for Q2 2025 and 2.59% for Q1 2025.